Last edition
News about
India’s small and mid-sized pharmaceutical manufacturers are raising alarms over new good manufacturing practice (GMP) and bio-equivalence mandates, warning that the regulations could widen the gap between large companies and micro, small, and medium enterprises (MSMEs).
Nasus Pharma Partners with Aptar to Strengthen Commercialisation of Intranasal Epinephrine
The collaboration aims to advance the clinical development and future commercialisation of NS002, Nasus Pharma’s intranasal powder epinephrine product candidate.
Natco Pharma to Acquire 35.75 Percent Stake in South Africa's Adcock Ingram, Delisting Planned
Natco Pharma has announced its intention to acquire a 35.75 percent equity stake in South Africa’s Adcock Ingram Holdings, in a deal valued at approximately INR 2,000 crore. This transaction is expected to make Natco the second-largest shareholder, while Bidvest will retain a 64.25 percent holding.
South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine
South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.
Through a novel public-private partnership, IAVI, Minapharm and ProBioGen will work together to bolster the innovation ecosystem on the continent and enable sustainable access to urgently-needed products.
Bristol Myers Squibb Acquires Orbital Therapeutics
The acquisition of Orbital Therapeutics by Bristol Myers Squibb includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogramme cells in vivo with potential best-in-class profile for autoimmune diseases.
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Smartee Denti-Technology Launches Innovative Sleep Aligners to Treat Sleep Apnoea and Snoring
Chinese dental technology company Smartee Denti-Technology has announced the global launch of its Smartee Sleep Aligners, a new clear aligner series designed to manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS).
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy